Market research
BJ93.F Benitec Biopharma Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 302K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.05
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US08205P1003
- Market cap
- 302K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.05
About
About Benitec Biopharma Inc
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BJ93.F discussion.
5 years, 5 months ago
Benitec Biopharma Inc is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.
From a valuation standpoint, the stock is 81.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 238.1.
Benitec Biopharma Inc's total revenue sank by 98.7% to $1K since the same quarter in the previous year.
Its net income has dropped by 51.3% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 11.3% to $-4M since the same quarter in the previous year.
Based on the above factors, Benitec Biopharma Inc gets an overall score of 1/5.